CAR T Cells: Second-Line Treatment Option for NHL? - NCI

Recent trial results suggest that CAR T cells may be superior to standard treatments for B-cell NHL that has not responded or has returned after treatment.

Impact of CD19 CAR T-cell product type on outcomes in relapsed or refractory aggressive B-NHL - ScienceDirect

Toward precision manufacturing of immunogene T-cell therapies - Cytotherapy

Health Care Resource Utilization and Total Costs of Care Among Patients with Diffuse Large B Cell Lymphoma Treated with Chimeric Antigen Receptor T Cell Therapy in the United States - Transplantation and

CAR T Cells: Engineering Immune Cells to Treat Cancer - NCI

Frontiers Targeted and cellular therapies in lymphoma: Mechanisms of escape and innovative strategies

CAR T Cells: Engineering Immune Cells to Treat Cancer - NCI

CAR T Cells: Second-Line Treatment Option for NHL? - NCI

CAR T Cells: Second-Line Treatment Option for NHL? - NCI

Prospects in the management of patients with follicular lymphoma beyond first-line therapy

CAR T-cell therapy in multiple myeloma: more room for improvement

Cancers, Free Full-Text

The CAR T Cell Story Published in healthbook TIMES Oncology Hematology